Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?

Current Opinion in Lipidology

Volumn 19, Issue 4, 2008, Pages 405-408

  Reddy, Srinivasa T ^a,b   Devarajan, Asokan ^a   Bourquard, Noam ^a   Shih, Diana ^a   Fogelman, Alan M ^a  

^a Atherosclerosis Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidant properties; Atherosclerosis; High density lipoprotein; Low density lipoprotein; Paraoxonases

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARAOXONASE 3; PROTEIN; RECOMBINANT ENZYME; SUPEROXIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DRUG MECHANISM; EXPRESSION VECTOR; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HETEROZYGOSITY; IN VIVO STUDY; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; LIPID PEROXIDATION; LIVER; MULTIGENE FAMILY; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE; ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM;

MUS;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; HUMANS;

EID: 53149114919     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328304b64e     Document Type: Review

References (16)

1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498-507.
2. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276:44444-44449.
3. Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38:153-163.
4. Rodrigo LB, Mackness PN, Durrington A, et al. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001; 354:1-7.
5. Rosenblat M, Draganov D, Watson CE, et al. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:468-474.
6. Horke S, Writte I, Wilegenbus P, et al. Paraoxonase 2 reduced oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007; 115:2055-2064. This study describes the potential role of PON2 in reducing oxidative stress and vascular inflammation.
7. Bourquard N, Shih DM, Ng CJ, et al. Paraoxonases and their role in disease development and xenobiotic metabolism. In: Mackness et al., editors. Proteins and cell regulation. vol. 6. New York: Springer; 2007. pp. 103-128. The role of PON2 and PON3 in atherosclerosis and related traits. This is an exhaustive review of all three PON genes.
8. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:23-28.
9. Shiner M, Fuhrman B, Aviram M. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation intomacrophages. Free Radic Biol Med 2004; 37:2052-2063.
10. Ng CJ, Villa N, Hama SY, et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-b containing lipoproteins - antiatherogenic role for paraoxonase-2. J Biol Chem 2006; 281:29491-29500.
11. Fisher EA, Pan M, Chen X, et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276:27855-27863.
12. Ng CJ, Hama SY, Navab M, et al. Paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein-E deficient mice. Mol Genet Metab 2006; 89:368-373.
13. Draganov DI, Stetson PL, Watson CE, et al. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein- associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275:33435-33442.
14. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL- associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21:542-547.
15. Ng CJ, Bourquard N, Villa N, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:1368-1374. This study shows that transient expression of PON3 is sufficient to reduce atherosclerosis in advanced atherosclerotic lesions in apoE null mice.
16. Shih DM, Xia Yr, Wang XP, et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Cir Res 2007; 100:1200-1207. This paper not only demonstrates the athero-protective nature of PON3 in transgenic mouse models but also shows that PON3 may be an important player in obesity as well.